Abstract
Abstract SELPLG is type I transmembrane receptor found on the surface of neutrophils, monocytes, and most lymphocytes. SELPLG interacts with P -selectin mediates the tethering and rolling of neutrophils, monocytes, and/or lymphocytes on endothelial cells. In whole exome sequencing analysis, we found that somatic mutation of SELPLG (2%) was found. Also its alternation (37%) was found in germline control group. rs201851784 of SELPLG polymorphism (43%) was determined in 118 adult AML patients and its polymorphism (12%) was determined in 1000 genome. The prevalence of the rs201851784 polymorphism was significantly different between AML patients and normal control (AA genotype vs. GG + AG genotype). Comparison analysis of SELPLG showed X-squared = 208.4140, df = 1 and p < 2.2e-16. After the IL-6 expression levels among AML patients were detected by ELISA, the allelic status and IL-6 expression on bone marrow serum of AML patients were analyzed. AML patient having A/G alternation was found to be associated with lower levels of IL-6 compared with AML patients having A/A. Those with persistence had higher IL-6 expression levels compared with those with CR in 1st induction (P < 0.05). In addition, there is a significant correlation between levels and SELPLG rs201851784, as analyzed by linear correlation assay. The AA genotype correlated with higher IL-6 levels (P < 0.05). Reverse correlation between SELPLG rs201851784 and IL-6 levels was found. SELPLG rs201851784 and IL-6 levels were also significantly correlated with OS. In conclusion, a polymorphism in the SELPLG gene related to cell dissemination and tissue infiltration is shown for the first time to be associated with susceptibility of AML and the overall survival. Citation Format: Sunghoon Cho, Chansu Lee, Hyun Choi, Kwang-Sung Ahn, Yongil Koh, Sung-Soo Yoon. In whole-exome sequencing analysis, alternations of P-selectin glycoprotein ligand 1 (SELPLG) significantly associates with inflammation and survival outcomes. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1107. doi:10.1158/1538-7445.AM2015-1107
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
